Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Rheumatic Heart Disease I: Introduction01:23

Rheumatic Heart Disease I: Introduction

24
Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
24
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

14
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
14
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

19
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
19
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

211
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
211
Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

247
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
247
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

1.7K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Human resistin is critical to activation of the NLRP3 inflammasome in macrophages.

PloS one·2026
Same author

Toll-like Receptor 7 Deficiency Attenuates Platelet Dysfunction in Sepsis.

Biomolecules·2025
Same author

CD44 signaling in skin wound healing and regeneration.

Journal of translational medicine·2025
Same author

G-protein-coupled receptor 41 in cardiomyocytes: Effect of butyrate on intracellular Ca<sup>2+</sup> and sarcomere shortening.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology·2024
Same author

HC-HA/PTX3 from Human Amniotic Membrane Induced Differential Gene Expressions in DRG Neurons: Insights into the Modulation of Pain.

Cells·2024
Same author

Ultrasound Shear Wave Elastography Evaluation of the Liver and Implications for Perioperative Medicine.

Journal of clinical medicine·2024
Same journal

Proteomics-Based Soluble Urokinase Plasminogen Activator Receptor Levels Are Associated With Adverse Cardiovascular Outcomes in the General Population: Insights From the UK Biobank.

Journal of the American Heart Association·2026
Same journal

Sex-Specific Association Between Socioeconomic Status and Stroke Mortality.

Journal of the American Heart Association·2026
Same journal

Social Determinants of Health and Cardiovascular Disease-Related Outcome Disparities Among Breast Cancer Survivors: A Systematic Review.

Journal of the American Heart Association·2026
Same journal

Graded Associations Between Left Ventricular Ejection Fraction Improvement and Cardiorenal Outcomes in Heart Failure With Improved Ejection Fraction.

Journal of the American Heart Association·2026
Same journal

Early Multimodal Motor Training After Stroke Promotes Motor Recovery and Whole-Brain Structural Remodeling.

Journal of the American Heart Association·2026
Same journal

EAT-Lancet Diet, Plasma Metabolites, and Risk of Peripheral Artery Disease: A Prospective Cohort Study.

Journal of the American Heart Association·2026
See all related articles

Related Experiment Video

Updated: Aug 6, 2025

A Model of Reverse Vascular Remodeling in Pulmonary Hypertension Due to Left Heart Disease by Aortic Debanding in Rats
07:41

A Model of Reverse Vascular Remodeling in Pulmonary Hypertension Due to Left Heart Disease by Aortic Debanding in Rats

Published on: March 1, 2022

3.0K

Human Resistin Induces Cardiac Dysfunction in Pulmonary Hypertension.

Qing Lin1, Santosh Kumar1, Udeshika Kariyawasam1

  • 1Department of Anesthesiology and Critical Care Medicine Johns Hopkins University School of Medicine Baltimore MD.

Journal of the American Heart Association
|March 17, 2023
PubMed
Summary
This summary is machine-generated.

Human resistin (Hresistin) directly causes cardiac dysfunction and remodeling in pulmonary arterial hypertension (PH). Targeting Hresistin with antibodies may treat PH-associated heart failure.

Keywords:
HMGB1RELMαcardiac remodelinginflammationright ventricle

More Related Videos

Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis
07:11

Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis

Published on: May 23, 2025

302
Rat Model of Right-Sided Cardiac Remodeling and Arrhythmia Using Pulmonary Artery Banding
10:39

Rat Model of Right-Sided Cardiac Remodeling and Arrhythmia Using Pulmonary Artery Banding

Published on: August 30, 2024

737

Related Experiment Videos

Last Updated: Aug 6, 2025

A Model of Reverse Vascular Remodeling in Pulmonary Hypertension Due to Left Heart Disease by Aortic Debanding in Rats
07:41

A Model of Reverse Vascular Remodeling in Pulmonary Hypertension Due to Left Heart Disease by Aortic Debanding in Rats

Published on: March 1, 2022

3.0K
Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis
07:11

Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis

Published on: May 23, 2025

302
Rat Model of Right-Sided Cardiac Remodeling and Arrhythmia Using Pulmonary Artery Banding
10:39

Rat Model of Right-Sided Cardiac Remodeling and Arrhythmia Using Pulmonary Artery Banding

Published on: August 30, 2024

737

Area of Science:

  • Cardiovascular Biology
  • Immunology
  • Molecular Medicine

Background:

  • Cardiac failure is a leading cause of death in pulmonary arterial hypertension (PH).
  • Resistin-like molecules are implicated in PH pulmonary vascular remodeling.
  • The direct role of resistin in PH-associated cardiac dysfunction remains unclear.

Purpose of the Study:

  • To investigate the direct role of human resistin (Hresistin) in cardiac dysfunction and remodeling in PH.
  • To explore the underlying mechanisms of Hresistin-induced cardiac pathology.
  • To evaluate the therapeutic potential of targeting Hresistin in PH models.

Main Methods:

  • Detection of Hresistin in human and rodent cardiac tissues.
  • Generation of a cardiac-specific Hresistin-overexpressing humanized mouse model.
  • Assessment of cardiac function, intracellular calcium handling, and molecular signaling pathways.
  • Evaluation of an anti-Hresistin antibody in rodent PH models.

Main Results:

  • Hresistin protein was detected in PH patient right ventricular (RV) tissue.
  • Cardiac Hresistin overexpression induced RV dysfunction, dilated hearts, reduced contractility, and impaired calcium transients.
  • Hresistin suppressed protein kinase A and AMP-activated protein kinase signaling.
  • Hresistin triggered inflammation via high-mobility group box 1 signaling and induced Ki67 expression.
  • An anti-Hresistin antibody protected against RV hypertrophy and failure in PH models.

Conclusions:

  • Hresistin is expressed in cardiac tissue and contributes to RV dysfunction and maladaptive remodeling in PH.
  • Hresistin's immunoregulatory activities are central to its cardiac effects.
  • Targeting Hresistin-mediated cardiac inflammation presents a potential therapeutic strategy for PH-associated heart failure.